Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pan-European Non-interventional, Retrospective Observational Cohort Study of Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Treated With Olaparib Tablets in the First-line Maintenance Setting

NCT04532645 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04532645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04532645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pan-European Non-interventional, Retrospective Observational Cohort Study of Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Treated With Olaparib Tablets in the First-line Maintenance Setting
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
January 7, 2021
Completion date
September 27, 2024
Enrollment
342 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

ovary cancer